Medworxx
Solutions Inc. ("Medworxx") (TSX VENTURE: MWX)
today announced a non-exclusive agreement with EY – formerly Ernst &
Young - to leverage each organisation’s expertise in Process Redesign
Optimisation. The Medworxx Clinical Utilisation Review (CUR) program is
widely accepted by hospitals and health systems internationally. The CUR
methodology leverages the Medworxx Clinical Criteria Module software
to unlock unique patient flow information to help organisations
understand the scope of their patient flow issues and identify specific
opportunities to improve quality and performance.
In the United Kingdom (UK), the introduction of the NHS England CQUIN
2015/2016 schedules presents a highly specialized opportunity for both
Medworxx and EY. The CQUIN demonstrates the NHS’ commitment to Clinical
Utilisation Review as an essential tool to affect patient flow
improvement by providing NHS Hospital Trusts with risk-free set-up
funding and ongoing financial support and incentives to develop and
embed robust Clinical Utilisation Review systems. EY will work with
Medworxx to introduce and implement the Medworxx CUR solution to the NHS
organisations.
“The CQUIN represents a great opportunity for CUR to be adopted rapidly
in the UK. As a leading Process and Redesign advisory service, EY is
positioned to help organisations realize their optimal potential. After
reviewing Medworxx results we strongly believe the combination of
expertise from both organisations will create a compelling overall
solution,” said, Joe Stringer, Partner, EY Healthcare Advisory, UK.
“Establishing partnerships with consulting companies is an important
component in our go to market strategy internationally,” said Dan
Matlow, President and Chief Executive Officer, Medworxx. “Having a
global partner like EY is validation of the value of our data.”
About EY
EY is a global leader in assurance, tax, transaction and advisory
services. The insights and quality services we deliver help build trust
and confidence in the capital markets and in economies the world over.
We develop outstanding leaders who team to deliver on our promises to
all of our stakeholders. In so doing, we play a critical role in
building a better working world for our people, for our clients and for
our communities.
EY refers to the global organisation and may refer to one or more of the
member firms of Ernst & Young Global Limited, each of which is a
separate legal entity. Ernst & Young Global Limited, a UK company
limited by guarantee, does not provide services to clients. For more
information about our organisation, please visit http://www.ey.com
.
About Medworxx
Medworxx delivers health information solutions to over 350 hospitals
internationally; including Canada, United States and United Kingdom.
Medworxx helps hospitals meet patient flow challenges, and requirements
in compliance and education. Medworxx Clinical Criteria – flagship of
Medworxx Patient Flow that includes electronic bed board and independent
assessment components – currently serves 32% of the acute care beds in
Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly
traded on the TSX Venture Exchange: MWX.
For more information visit: http://www.medworxx.com.
Disclaimer
The statements made in this press release may contain forward-looking
statements that may involve a number of risks and uncertainties. Actual
events or results could differ materially from the company’s
expectations and projections. The TSX Venture Exchange has not reviewed
this press release and neither approved nor disapproved the information
contained in this press release.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150407005204r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2015